Diabetic Macular Edema

SFChT in treatment-naïve eyes was positively associated with eGFR and diabetic retinopathy grade.

In a comparison with manual human grading, investigators find machine learning model produced no statically significant differences in Dice coefficients.

An interview with a Cleveland Clinic investigator on adjusting macular edema screening methods.

A perspective on what's moved virtually, and what hasn't, since the pandemic began in March.

An interview with a Cleveland Clinic investigator on adjusting macular edema screening methods.

Interim findings from a cross-sectional study shows a correlation between worse cognitive scoring and a greater rate of intravitreal injections.

A total of 115 of 200 examined eyes had some form of diabetic retinopathy in data presented at the ASRS 2020 virtual meeting.

In research presented at ASRS 2020, investigators found 56% of patients with PDR had a DME code, with a sensitivity of 85%.

A new analysis of a trio of intravitreal agents show maintained visual acuity in treatment-naive patients for at least 5 years.

The specialty is on the precipice of advancement. What gets it over the hurdle?

In a study presented at ASRS 2020, investigators find an improvement in DRSS is not correlated with a change in best corrected visual acuity.

Steroids are often prescribed for diabetic macular edema following ineffectiveness of laser photocoagulation and anti-VEGF.

A large proportion of nAMD patients treated with anti-VEGF therapies continue to have active disease and fluid.

In data presented virtually during the ASRS 2020 meeting, investigators find X-82 is non inferior in visual acuity outcomes.

A look at how the specialty functions in telemedicine, and how it could work better with primary care physicians and endocrinologists.

How the condition affects both the vision and mindset of patients, and what clinical outcomes for anti-VEGF research do to address it.

A look at how primary care patients begin to present with diabetic retinopathy risk.

New PANORAMA findings could give ophthalmologists confidence in longer time between administrations after year 2.

For the EMB treatment group, 65.6% of participants (n = 160) lost fewer than 15 ETDRS letters, while 86.6% (n = 103) in the ranibizumab group lost fewer than 15 ETDRS letters.

New research from ARVO 2020 suggests patients with diabetic eye disease can still experiences losses in visual acuity, even with glycemic control.

Gauging patient wellbeing prior to intravitreal injections may help inform clinicians as to who may fare worse with the treatment.

A new assessment shows about 60% of treatment-naive patients are not prescribed the most common drug class within 1 year of secondary edema.

A Q&A with Anne Fung, MD, Global Development Lead for the Port Delivery System with ranibizumab at Genentech.

A new study from the University of Rochester indicates early intervention could help preserve or even restore visual abilities in stroke patients.

New research suggests the presence of either condition can wreak havoc on an older adult's ability for movement, self-care, and household activities.